Pancreatic Ductal Adenocarcinoma

MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma.

CONTEXT Cytological assessment of pancreatic juice is commonly used to diagnose pancreatic ductal adenocarcinoma; however, the sensitivity of cytological assessment has been reported to be low. MicroRNAs are small RNAs regulating various cellular processes and have recently been identified as possible markers of malignant diseases including pancreatic ductal adenocarcinoma. OBJECTIVE The purp...

Identification of a Novel Subpopulation of Tumor-Initiating Cells from Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Patients

Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from chemotherapy-resistant patients remain unclear. In this study, we set out to establish a cancer cell line in disseminated cancer cells derived from gemc...

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma

BACKGROUND Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic cholangiocarcinomas. Given the close anatomical relationship between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, we therefore sough...

Palliative Resection of Pancreatic Adenocarcinoma

A survey was carried out by postal questionnaire of the attitudes of British surgeons to pancreatic resection as palliation for ductal adenocarcinoma of the pancreas. Replies from 24 surgeons related to experience in over 700 resections. The incidence of estimated residual local disease after resection was median 12.5 percent, range 0-35 percent. Half (12) of the surgeons felt that pancreatic r...

Proteomic analysis identified up-regulated MMP-9 and DJ-1 proteins in pancreatic juice from pancreatic ductal adenocarcinoma

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma

Macrophages are critical proponents of the growth and development of pancreatic ductal adenocarcinoma. However, if properly instructed, macrophages can acquire anti-tumor properties, including the capacity to degrade the fibrous matrix that surrounds neoplastic lesions and to eliminate malignant cells, eventually leading to tumor regression.